Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 6/20 | 0.53 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.37 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL850962 | 0.88 | PTH1R (0.51) | PTH1RCALCRLALDH1A1 | |
| SCHEMBL850961 | 0.88 | PTH1R (0.51) | PTH1RCALCRLALDH1A1 | |
| SCHEMBL13064846 | 0.86 | PTH1R (0.48) | PTH1RGFERCALCRLALDH1A1 | |
| SCHEMBL879773 | 0.86 | PTH1R (0.49) | PTH1RCALCRLALDH1A1 | |
| SCHEMBL848083 | 0.86 | PTH1R (0.51) | PTH1RCALCRL | |
| SCHEMBL848084 | 0.86 | PTH1R (0.51) | PTH1RCALCRL | |
| SCHEMBL13555060 | 0.84 | PTH1R (0.51) | PTH1RCALCRL | |
| SCHEMBL13555084 | 0.84 | PTH1R (0.48) | PTH1R | |
| SCHEMBL847186 | 0.84 | PTH1R (0.48) | PTH1RCALCRLALDH1A1 | |
| SCHEMBL847187 | 0.84 | PTH1R (0.48) | PTH1RCALCRLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PTH1R 1869/4885IP6K1 3018/4885MRGPRX2 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.